Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare, Medicaid and generally, including proposed reform proposals.
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Duration: November 1, 2007
to
December 31, 2019
General Issues: Medicare/Medicaid , Trade (Domestic & Foreign) , Taxation/Internal Revenue Code , Health Issues , Animals , Medical/Disease Research/Clinical Labs , Copyright/Patent/Trademark
Spending: about $1,710,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2007: U.S. Senate, House of Representatives, U.S. Senate,, Y
Y
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Charles Brain Asst. to the President, Dp.Chief Staff W&M Cmte
Asst. to the President,Dp.Chief Staff W&MCmte.
NA
Special Assistant to the President, Deputy Chief of Staff House Ways and Means Committee
Special Assistant to the President, Deputy Chief of Staff House Ways & Means Committee
Special Assistant to the President; Deputy COS Ways & Means Committee
A. J. Wojciak Senior Legislative Asst., Cong. Earl Pomeroy
NA
Beau Schuyler LD-CongTanner, LD-CongMcIntyre,SA-CongRose
LD-CongTanner,LD-CongMcIntyre,SA-CongRose
LD-Cong. John Tanner, LD-Cong. Mike McIntyre
LD-CongTanner,LD-CongMcIntyre,LD-CongRose
Legislative Director, Rep. John Tanner; Legislative Director, Rep. Mike McIntyre; Senior Legislative Aide, Rep. Charlie Rose
Legislative Director for Rep. John Tanner
Legislative Director to Rep. John Tanner
Heather McHugh Legislative Director, Sen. Chuck Schumer
Legislative Director, Sen. Chuck Shumer
Legislative Director, Senator Chuck Schumer
Legislative Director for Senator Charles Schumer
Legislative Director to Senator Charles Schumer
A.J. Wojciak Senior Legislative Asst., Cong. Earl Pomeroy
NA
Senior Legislative Aide, Rep. Earl Pomeroy
Senior Legislative Aide to Rep. Earl Pomeroy
Paul Bock Chief of Staff, Sen. Kohl
CHARLES M. BRAIN Assistant to the President, Deputy Chief of Staff W&M Committee
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2019
Capitol Hill Strategies, LLC terminated an engagement in which they represented MERCK & CO., INC on Jan. 16, 2020.
Original Filing: 301107219.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare, Medicaid and generally, including proposed reform proposals.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2019
In Q3, Capitol Hill Strategies, LLC lobbied for MERCK & CO., INC , earning $40,000. The report was filed on Oct. 16, 2019.
Original Filing: 301066269.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare, Medicaid and generally, including proposed reform proposals.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2019
In Q2, Capitol Hill Strategies, LLC lobbied for MERCK & CO., INC , earning $40,000. The report was filed on July 19, 2019.
Original Filing: 301051650.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare, Medicaid and generally, including proposed reform proposals.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2019
In Q1, Capitol Hill Strategies, LLC lobbied for MERCK & CO., INC , earning $40,000. The report was filed on April 22, 2019.
Original Filing: 301037951.xml
Lobbying Issues
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight.
H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements.
H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity.
H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book
H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date
H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing
H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019, provisions relating to prescription drug pricing and intellectual property rights.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Capitol Hill Strategies, LLC lobbied for MERCK & CO., INC , earning $40,000. The report was filed on Feb. 27, 2019.
Original Filing: 301020794.xml
Lobbying Issues
H.R. 6, Legislation to address opioids manufacturing and distribution
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA), vaccines and other various provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.
H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Animal Drug and Animal Generic Drug User Fee Re-authorization Act, various provisions.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Capitol Hill Strategies, LLC lobbied for MERCK & CO., INC , earning $40,000. The report was filed on Oct. 18, 2018.
Original Filing: 300988916.xml
Lobbying Issues
H.R. 6, Legislation to address opioids manufacturing and distribution
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA), vaccines and other various provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.
H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Animal Drug and Animal Generic Drug User Fee Re-authorization Act, various provisions.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Capitol Hill Strategies, LLC lobbied for MERCK & CO., INC , earning $40,000. The report was filed on July 20, 2018.
Original Filing: 300974461.xml
Lobbying Issues
H.R. 6, Legislation to address opioids manufacturing and distribution
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA), vaccines and other various provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.
H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Animal Drug and Animal Generic Drug User Fee Re-authorization Act, various provisions.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Capitol Hill Strategies, LLC lobbied for MERCK & CO., INC , earning $40,000. The report was filed on April 19, 2018.
Original Filing: 300949626.xml
Lobbying Issues
Legislation to address opioids manufacturing and distribution
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA), vaccines and other various provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.
H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Animal Drug and Animal Generic Drug User Fee Re-authorization Act, various provisions.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
Capitol Hill Strategies, LLC filed a lobbying registration on March 5, 2018 to represent MERCK & CO., INC, effective Jan. 1, 2018.
Original Filing: 300940957.xml
Issue(s) they said they’d lobby about: Provide legislative and policy counsel for advocacy relating to regulations and legislation of interest to Merck and the pharmaceutical industry, particularly as relates to Medicare Part D and the Affordable Care Act. .
3rd Quarter, 2015
Capitol Hill Strategies, LLC terminated an engagement in which they represented MERCK & CO., INC on Oct. 20, 2015.
Original Filing: 300765163.xml
2nd Quarter, 2015
In Q2, Capitol Hill Strategies, LLC did no lobbying for MERCK & CO., INC . The report was filed on July 21, 2015.
Original Filing: 300747051.xml
1st Quarter, 2015
In Q1, Capitol Hill Strategies, LLC lobbied for MERCK & CO., INC , earning $50,000. The report was filed on April 15, 2015.
Original Filing: 300716130.xml
Lobbying Issues
Potential legislation or legislative provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs)
H. Con. Res. 27, Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025 (potential provisions relating to Medicare Part D and the establishment of a Medicaid style rebate, NIH funding provisions drawing funds from BIO/PhRMA industry government settlements, or other Medicare revenue raising provisions)
S. Con. Res. 11, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025 (potential provisions relating to Medicare Part D and the establishment of a Medicaid style rebate, NIH funding provisions drawing funds from BIO/PhRMA industry government settlements, or other Medicare revenue raising provisions)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Draft 21st Century Cures legislation under consideration by the House Energy & Commerce Committee (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies)
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2014
In Q4, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $50,000. The report was filed on Jan. 20, 2015.
Original Filing: 300703112.xml
Lobbying Issues
Comprehensive Tax Reform Legislation, generally.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H. Con. Res. 96, Establishing the budget for the United States Government for fiscal year 2015 and setting forth appropriate budgetary levels for fiscal years 2016 through 2024, (potential provisions relating to Medicare Part D and the establishment of a Medicaid style "rebate").
S. 2110, Medicare SGR Repeal and Beneficiary Access Improvement Act (potential programmatic offsets).Potential deficit reduction legislation that might include provisions to reduce Medicare Part B reimbursements for drugs and biologics.
H.R.1588, Medicare Drug Savings Act of 2013 (provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs).
H.R. 4302, Protecting Access to Medicare Act of 2014, (potential programmatic offsets).
H.R. 4187, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014
H.R. 83, Consolidated and Further Continuing Appropriations Act, 2015 (potential programmatic offsets).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to international market access for vaccines.
Issues related to the Trans-Pacific Partnership trade agreement.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2014
In Q3, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $50,000. The report was filed on Oct. 17, 2014.
Original Filing: 300680326.xml
Lobbying Issues
Comprehensive Tax Reform Legislation, generally.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H. Con. Res. 96, Establishing the budget for the United States Government for fiscal year 2015 and setting forth appropriate budgetary levels for fiscal years 2016 through 2024, (potential provisions relating to Medicare Part D and the establishment of a Medicaid style "rebate").
S. 2110, Medicare SGR Repeal and Beneficiary Access Improvement Act (potential revenue raising provisions).Potential deficit reduction legislation that might include provisions to reduce Medicare Part B reimbursements for drugs and biologics.
H.R.1588, Medicare Drug Savings Act of 2013 (provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs).
H.R. 4302, Protecting Access to Medicare Act of 2014, (potential revenue raising provisions).
H.R. 4187, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to international market access for vaccines.
Issues related to the Trans-Pacific Partnership trade agreement.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2014
In Q2, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $50,000. The report was filed on July 18, 2014.
Original Filing: 300661183.xml
Lobbying Issues
Comprehensive Tax Reform Legislation, generally.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H. Con. Res. 96, Establishing the budget for the United States Government for fiscal year 2015 and setting forth appropriate budgetary levels for fiscal years 2016 through 2024, (potential provisions relating to Medicare Part D and the establishment of a Medicaid style "rebate").
S. 2110, Medicare SGR Repeal and Beneficiary Access Improvement Act (potential revenue raising provisions).Potential deficit reduction legislation that might include provisions to reduce Medicare Part B reimbursements for drugs and biologics.
H.R.1588, Medicare Drug Savings Act of 2013 (provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs).
H.R. 4302, Protecting Access to Medicare Act of 2014, (potential revenue raising provisions).
H.R. 4187, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the approval of beta agonists in Taiwan.
Issues related to the Trans-Pacific Partnership trade agreement.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R. 3309, Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2014
In Q1, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $50,000. The report was filed on April 17, 2014.
Original Filing: 300639322.xml
Lobbying Issues
Comprehensive Tax Reform Legislation, generally.
S. 1658, Start-up Jobs and Innovation Act, legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities.
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment of net operating losses of high technology research small businesses corporations.
S. 1658, Start-up Jobs and Innovation Act, legislation to amend the Internal Revenue Code of 1986 to modernize Section 1202 regarding the exclusion for gain from certain small business stock.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H. Con. Res. 96, Establishing the budget for the United States Government for fiscal year 2015 and setting forth appropriate budgetary levels for fiscal years 2016 through 2024, (potential provisions relating to Medicare Part D and the establishment of a Medicaid style "rebate").
S. 2110, Medicare SGR Repeal and Beneficiary Access Improvement Act (potential revenue raising provisions).Potential deficit reduction legislation that might include provisions to reduce Medicare Part B reimbursements for drugs and biologics.
H.R.1588, Medicare Drug Savings Act of 2013 (provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs).
H.R. 4302, Protecting Access to Medicare Act of 2014, (potential revenue raising provisions).
H.R. 4187, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014 (add on incentive payment for last line of defense antibiotic treatments).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the approval of beta agonists in Taiwan.
Issues related to the Trans-Pacific Partnership trade agreement.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R. 3309, Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2013
In Q4, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $50,000. The report was filed on Jan. 16, 2014.
Original Filing: 300616923.xml
Lobbying Issues
H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013 (state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions)
S.959, Pharmaceutical Compounding Quality and Accountability Act ((state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions, compounding oversight provisions)H.R. 3204, Drug Quality and Security Act (state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions)
H.R. 2725, Food and Drug Administration Safety Over Sequestration Act of 2013 (exempting industry funded user fees from sequester)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023, (Provisions relating to Medicare Part D and the establishment of a Medicaid style rebate)Potential deficit reduction legislation that might include provisions to reduce Medicare Part B reimbursements for drugs and biologics
H.R.1588, Medicare Drug Savings Act of 2013 (provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the approval of beta agonists in Taiwan.
Issues related to the Trans-Pacific Partnership trade agreement.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2013
In Q3, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $50,000. The report was filed on Oct. 17, 2013.
Original Filing: 300596369.xml
Lobbying Issues
H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013 (state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions)
S.959, Pharmaceutical Compounding Quality and Accountability Act ((state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions, compounding oversight provisions)H.R. 3204, Drug Quality and Security Act (state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions)
H.R. 2725, Food and Drug Administration Safety Over Sequestration Act of 2013 (exempting industry funded user fees from sequester)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023, (Provisions relating to Medicare Part D and the establishment of a Medicaid style rebate)Potential deficit reduction legislation that might include provisions to reduce Medicare Part B reimbursements for drugs and biologics
H.R.1588, Medicare Drug Savings Act of 2013 (provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the approval of beta agonists in Taiwan.
Issues related to the Trans-Pacific Partnership trade agreement.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2013
In Q2, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $50,000. The report was filed on July 18, 2013.
Original Filing: 300576133.xml
Lobbying Issues
H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013 (state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions)
S.959, Pharmaceutical Compounding Quality and Accountability Act ((state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions, compounding oversight provisions)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023, (Provisions relating to Medicare Part D and the establishment of a Medicaid style rebate)Potential deficit reduction legislation that might include provisions to reduce Medicare Part B reimbursements for drugs and biologics
H.R.1588, Medicare Drug Savings Act of 2013 (provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the approval of beta agonists in Taiwan.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2013
In Q1, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $50,000. The report was filed on April 18, 2013.
Original Filing: 300553841.xml
Lobbying Issues
Proposed legislation related to supply chain safety of pharmaceuticals and biologics, as considered in S. 3187 and related bills
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023, (Provisions relating to Medicare Part D and the establishment of a Medicaid style rebate)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $50,000. The report was filed on Jan. 18, 2013.
Original Filing: 300533001.xml
Lobbying Issues
Proposed legislation related to supply chain safety of pharmaceuticals and biologics, as considered in S. 3187 and related bills
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
.R.6156, the Russia and Moldova Jackson-Vanik Repeal and Sergei Magnitsky Rule of Law Accountability Act of 2012
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2012
In Q3, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $50,000. The report was filed on Oct. 17, 2012.
Original Filing: 300509041.xml
Lobbying Issues
Proposed legislation related to Supply chain safety of pharmaceuticals and biologics, as considered in S. 3187 and related bills
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation to grant Permanent Normal Trade Relations status to Russia
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2012
In Q2, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $50,000. The report was filed on July 17, 2012.
Original Filing: 300486430.xml
Lobbying Issues
H.R. 5651, Food and Drug Administration Reform Act of 2012 (provisions related to supply chain safety, exclusivity and incentives for pediatric drugs, drug shortages and the underlying PDUFA reauthorization agreement)S. 3187, Food and Drug Administration Safety and Innovation Act (provisions related to supply chain safety, pediatric drugs, drug shortages and the underlying PDUFA reauthorization agreement; potential amendments/provisions including patent settlements and importation)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $50,000. The report was filed on April 18, 2012.
Original Filing: 300464618.xml
Lobbying Issues
H.R. 452, To repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board. Prescription Drug User Fee Act Reauthorization legislation underlying reauthorization for FDA approval process and other issues that are being considered for inclusion in the legislative package such as up and downstream supply chain safety, pediatric exclusivity and incentive provisions, track and trace provisions, and drug shortages provisions.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.3630, Temporary Payroll Tax Cut Continuation Act of 2011 (Medicare Part D provisions; Medicare Part B drug reimbursements)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $50,000. The report was filed on Jan. 19, 2012.
Original Filing: 300444800.xml
Lobbying Issues
H.R. 452, To repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board
H.R.2112 Consolidated and Further Continuing Appropriations Act, 2012 (S.AMDT.769, Sen. Vitter Amendment on pharmaceutical importation)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3080, United States-Korea Free Trade Agreement Implementation Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Negotiations of the Joint Select Committee on Deficit Reduction (Medicare Part D provisions; Medicare Part B drug reimbursements)
H.R.3630, Temporary Payroll Tax Cut Continuation Act of 2011 (Medicare Part D provisions; Medicare Part B drug reimbursements)
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $50,000. The report was filed on Oct. 18, 2011.
Original Filing: 300417131.xml
Lobbying Issues
H.R. 452, To repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1249, Leahy-Smith America Invents Act
S.23, America Invents Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Korean Free Trade Agreement
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Bipartisan, bicameral negotiations on legislative framework for comprehensive deficit reduction (Medicare Part D provisions; Medicare Part B drug reimbursements)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $40,000. The report was filed on July 15, 2011.
Original Filing: 300391275.xml
Lobbying Issues
H.R. 452, To repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1249, Leahy-Smith America Invents Act
S.23, America Invents Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Korean Free Trade Agreement
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2011
In Q1, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $40,000. The report was filed on April 19, 2011.
Original Filing: 300371206.xml
Lobbying Issues
H.R. 452, To repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2010
In Q4, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $40,000. The report was filed on Jan. 17, 2011.
Original Filing: 300339275.xml
Lobbying Issues
H.R. 3590, the Patient Protection and Affordable Care Act (membership and formation of comparative effectiveness research entity, the Patient-Centered Outcomes Research Institute (PCORI) created in this law)
H.Res. 1302, Supporting the goals and ideals of National Hepatitis Awareness Month and World Hepatitis Day
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.4853, Tax Relief, Unemployment Insurance Reauthorization, and Job Creation Act of 2010 (issues related to payfors)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2010
In Q3, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $40,000. The report was filed on Oct. 12, 2010.
Original Filing: 300310975.xml
Lobbying Issues
H.R. 4899, the Supplemental Appropriations Act of 2010 (340b provisions, BioShield funding, AMP provisions)
H.Res. 1302, Supporting the goals and ideals of National Hepatitis Awareness Month and World Hepatitis Day
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4213, Unemployment Compensation Extension Act of 2010 (340b provisions)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2010
In Q2, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $40,000. The report was filed on July 15, 2010.
Original Filing: 300287274.xml
Lobbying Issues
H.R. 4899, the Supplemental Appropriations Act of 2010 (BioShield funding, AMP provisions)
H.Res. 1302, Supporting the goals and ideals of National Hepatitis Awareness Month and World Hepatitis Day
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010 (340b provisions)
H.R. 4899, the Supplemental Appropriations Act of 2010 (340b provisions)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2010
In Q1, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $40,000. The report was filed on April 18, 2010.
Original Filing: 300261812.xml
Lobbying Issues
H.R. 3590, the Patient Protection and Affordable Care Act of 2009 (Comparative Effectiveness Research, Vaccine provisions, Follow on Biologics, 340B provisions)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2009
In Q4, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $40,000. The report was filed on Jan. 18, 2010.
Original Filing: 300234429.xml
Lobbying Issues
H.R. 1548, Pathway for Biosimilars Act of 2009
H.R. 1427, Promoting Innovation and Access to Life-saving Medicines Act
H.R. 2502, Comparative Effectiveness Research Act of 2009
S. 1213, Patient-Centered Outcomes Research Act of 2009H.R. 3590, the Patient Protection and Affordable Care Act of 2009 (Comparative Effectiveness Research, Vaccine, Follow on Biologics)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1679, the Affordable Health Choices Act (Comparative Effectiveness Research, Part D provisions, 340B provisions, Follow on biologics)
H.R. 3962, America's Affordable Health Choices Act of 2009 (Comparative Effectiveness Research, Part D provisions, 340B provisions, Follow on Biologics )
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
In Q3, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $40,000. The report was filed on Oct. 16, 2009.
Original Filing: 300208536.xml
Lobbying Issues
H.R. 1548, Pathway for Biosimilars Act of 2009
H.R. 1427, Promoting Innovation and Access to Life-saving Medicines Act
H.R. 2502, Comparative Effectiveness Research Act of 2009
S. 1213, Patient-Centered Outcomes Research Act of 2009S. ____, Americas Healthy Future Act of 2009 (Comparative Effectiveness Research)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1679, the Affordable Health Choices Act (Vaccine Coverage under Medicare Part B)
H.R. 3200, America's Affordable Health Choices Act of 2009 (Vaccine Coverage under Medicare Part B)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
In Q2, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $50,000. The report was filed on July 15, 2009.
Original Filing: 300178803.xml
Lobbying Issues
H.R. 1548, Pathway for Biosimilars Act of 2009
H.R. 1427, Promoting Innovation and Access to Life-saving Medicines Act
H.R. 2502, Comparative Effectiveness Research Act of 2009
S. 1213, Patient-Centered Outcomes Research Act of 2009S. ____ [Draft of HELP Committee health care reform bill], Affordable Health Choices Act (Biologics Price Competition and Innovation provisions)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3200, Americas Affordable Health Choices Act (Comparative Effectiveness Research, Medicare Part D, Vaccine Coverage in Medicare)
S. ____, Senate Finance Committee Health Care Reform Options (Comparative Effectiveness Research, Vaccine Coverage in Medicare)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
In Q1, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $50,000. The report was filed on April 17, 2009.
Original Filing: 300153776.xml
Lobbying Issues
H.R. 1548, Pathway for Biosimilars Act of 2009
H.R. 1427, Promoting Innovation and Access to Life-saving Medicines Act
H.R. 629, Energy and Commerce Recovery and Reinvestment Act (Medicare Part D provisions)
H.R. 2, Children's Health Insurance Program Reauthorization Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1, American Recovery and Reinvestment Act of 2009 (Comparative Effectiveness Research Provisions)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2008
In Q4, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $50,000. The report was filed on Jan. 14, 2009.
Original Filing: 300118447.xml
Lobbying Issues
H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007 (Follow on Biologics)
H.R. 5629, Pathway for Biosimilars Act (Follow on Biologics)
H.R. 1038, Access to Life-Saving Medicine Act (Follow on Biologics)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 6381, Medical Device Safety Act of 2008 (Pre-emption legislation to overturn Riegel v. Medtronic)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H.R. 1424, Emergency Economic Stabilization Act of 2008, (Paul Wellstone Mental Health and Addiction Equity title - Medicaid rebate)
H.R. 6983, Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (Medicaid Rebate)
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2008
In Q3, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $50,000. The report was filed on Oct. 8, 2008.
Original Filing: 300089134.xml
Lobbying Issues
H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007 (Follow on Biologics)
H.R. 5629, Pathway for Biosimilars Act (Follow on Biologics)
H.R. 1038, Access to Life-Saving Medicine Act (Follow on Biologics)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 6381, Medical Device Safety Act of 2008 (Pre-emption legislation to overturn Riegel v. Medtronic)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H.R. 6331, Medicare Improvements for Patients and Providers Act of 2008 (Preventive Care provisions)
H.R. 1424, Paul Wellstone Mental Health and Addiction Equity Act of 2008 (Medicaid Rebate)
H.R. 6983, Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (Medicaid Rebate)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2008
In Q2, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $50,000. The report was filed on July 16, 2008.
Original Filing: 300067289.xml
Lobbying Issues
H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007
H.R. 5629, Pathway for Biosimilars Act; H.R. 1038, Access to Life-Saving Medicine Act; (Follow on Biologics)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 6381, Medical Device Safety Act of 2008 (Pre-emption legislation to overturn Riegel v. Medtronic)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H R. 6331, The Medicare Improvements for Patients and Providers Act of 2008
H.R. 1424, Paul Wellstone Mental Health and Addiction Equity Act of 2008; (Medicaid Rebate)
H.R. 3162, CHAMP Act; Baucus-Conrad bill (draft released, not introduced); H.R. 2184, Enhanced Health Care Value for All Act of
2007; (Comparative Effectiveness provisions of each)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2008
In Q1, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $50,000. The report was filed on April 18, 2008.
Original Filing: 300044712.xml
Lobbying Issues
Medicare Reimbursement and Coverage Issues
Medicaid Rebate: Mental Health Parity bill (H.R. 1424)
Comparative Effectiveness: CHAMP Act (H.R. 3162); Baucus-Conrad bill(proposed, not yet introduced); Allen bill (H.R.2184)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Follow on Biologic legislation:
H R. 1038 Access to Life-saving Medicines Act
H.R. 1956 Patient Protection and Innovative Biologics Medicines Act of 2007
H.R. 5629 Pathway for Biosimilars Act
Agencies Lobbied
U.S. Senate
0th Quarter, 2007
In MM, CAPITOL HILL STRATEGIES, LLC lobbied for MERCK & CO., INC , earning $100,000. The report was filed on July 29, 2007.
Original Filing: 200042221.xml
Lobbying Issues
Medicare Reimbursement and Coverage Issues
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...